Literature DB >> 10328813

HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction.

M Götte1, X Li, M A Wainberg.   

Abstract

An early step in the life cycle of the human immunodeficiency virus type 1 (HIV-1) is reverse transcription of viral RNA into proviral DNA, which can then be integrated into the host cell genome. Reverse transcription is a discontinuous process carried out by the viral encoded reverse transcriptase that displays DNA polymerase activities on RNA and DNA templates as well as an RNase H activity that degrades transcribed RNA. DNA synthesis is initiated by cellular tRNALys3 that binds at its 3'-terminus to the complementary primer binding site of the genomic RNA. The initiation of reverse transcription is itself a complex reaction that requires tRNA placement onto viral RNA and the formation of a specific primer/template complex that is recognized by reverse transcriptase. After initiation takes place, the enzyme translocates from the initially bound RNA/RNA duplex into chimeric replication intermediates and finally accommodates newly synthesized DNA/RNA hybrids. This review focuses on structure-function relationships among these various molecules that are involved in the initiation of HIV-1 reverse transcription. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328813     DOI: 10.1006/abbi.1999.1209

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  36 in total

1.  The effect of mutations in the HIV-1 nucleocapsid protein on strand transfer in cell-free reverse transcription reactions.

Authors:  M Hsu; L Rong; H de Rocquigny; B P Roques; M A Wainberg
Journal:  Nucleic Acids Res       Date:  2000-04-15       Impact factor: 16.971

2.  Human immunodeficiency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers.

Authors:  X Wei; M Götte; M A Wainberg
Journal:  Nucleic Acids Res       Date:  2000-08-15       Impact factor: 16.971

3.  N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.

Authors:  Mia J Biondi; Greg L Beilhartz; Suzanne McCormick; Matthias Götte
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

4.  Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.

Authors:  Jiong Wang; Robert A Bambara; Lisa M Demeter; Carrie Dykes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

5.  Interaction between Reverse Transcriptase and Integrase Is Required for Reverse Transcription during HIV-1 Replication.

Authors:  Shewit S Tekeste; Thomas A Wilkinson; Ethan M Weiner; Xiaowen Xu; Jennifer T Miller; Stuart F J Le Grice; Robert T Clubb; Samson A Chow
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

6.  Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription.

Authors:  Charles W Dobard; Marisa S Briones; Samson A Chow
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

7.  Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones.

Authors:  Joël Didierjean; Catherine Isel; Flore Querré; Jean-François Mouscadet; Anne-Marie Aubertin; Jean-Yves Valnot; Serge R Piettre; Roland Marquet
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

8.  Functional organization of repeat addition processivity and DNA synthesis determinants in the human telomerase multimer.

Authors:  Tara J Moriarty; Delphine T Marie-Egyptienne; Chantal Autexier
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

9.  Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G.

Authors:  Guylaine Haché; Truus E M Abbink; Ben Berkhout; Reuben S Harris
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.

Authors:  Ming-Tain Lai; Vandna Munshi; Sinoeun Touch; Robert M Tynebor; Thomas J Tucker; Philip M McKenna; Theresa M Williams; Daniel J DiStefano; Daria J Hazuda; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.